



Dedicated To Life

May 13, 2026

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Ref.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) read with SEBI Master Circular dated November 11, 2024 (“the SEBI Circular”) – Acquisition.**

Dear Sir / Madam,

With reference to the captioned subject, this is to inform that Zydus Worldwide DMCC (“**Zydus Worldwide**”), a subsidiary of Zydus Lifesciences Limited (“the **Company**”) has signed a definitive agreement, through its wholly owned acquisition subsidiary Zara Merger Sub Inc., (“**Zara**”) (Zydus Worldwide, Zara and the Company are collectively referred to as “**Zydus**”) with Assertio Holdings, Inc. (“**Assertio**”), to acquire all outstanding shares of Assertio for USD 23.50 per share in cash representing total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method.

Assertio is a U.S. based pharmaceutical company focused on specialty and oncology supportive-care therapies (NASDAQ: ASRT) with its novel product ROLVEDON® (eflapegrastim xnst), approved as BLA by USFDA for long-acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. The equity shares of Assertio are listed on Nasdaq with code “ASRT”.

This transaction has been approved by the Boards of Directors of both Zydus Worldwide and Assertio and it is structured as a tender offer to be followed by a merger, subject to customary closing conditions and regulatory approvals.

This transaction will help Zydus to secure an **immediate U.S. specialty oncology commercial footprint** and use it as a platform to expand an oncology specialty portfolio. Assertio’s **170+ community oncology accounts** and **buy-and-bill infrastructure** offers a “ready-made” base to build a broader oncology platform.

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Requisite details as required to be disclosed pursuant to the provisions of regulation 30 of the Listing Regulations read with para A of part A of Schedule of the Listing Regulations and para 1.1 of Annexure 18 of the SEBI Circular are provided in **Annexure-“1”**.

Press Release in this regard is attached as **Annexure-“2”**.

Yours faithfully,  
For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Encl.:** As above

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



**Annexure-“1”-Acquisition of Shares of Assertio**

Sr. No.	Particulars	Responses
1.	Name of the target entity, details in brief such as size, turnover etc.:	Assertio Holdings, Inc., (“ <b>Assertio</b> ”) is a Nasdaq listed (Nasdaq: ASRT) pharmaceutical company having its registered office in Delaware, USA.  Assertio is a US specialty oncology company.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:	The proposed acquisition does not fall within related party transactions.  None of the promoter / promoter group / group companies have any interest in the proposed acquisition.
3.	Industry to which the entity being acquired belongs:	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	The proposed acquisition of Assertio is in line with Zydus’s strategic objective on building a speciality oncology company.  Assertio’ s 170+ community oncology accounts and buy-and-bill infrastructure offers a ready-made base to build a broader oncology platform.
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	The proposed acquisition is subject to customary closing conditions, including the tender of a majority of the Company’s outstanding shares.
6.	Indicative time period for completion of the acquisition:	The acquisition is expected to be completed in the financial year 2026-27 subject to customary conditions.
7.	Consideration-whether cash consideration or share swap or any other form and details of the same:	Cash consideration  The transaction is proposed to be implemented through a tender offer to be followed by a merger pursuant to which, Zara will merge with and into Assertio, with Assertio continuing as the surviving corporation.



		Upon successful completion of the transaction, Assertio will be delisted from Nasdaq.								
8.	Cost of acquisition and/or the price at which the shares are acquired:	USD 23.50 per share in cash, representing total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method.								
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	100% of outstanding shares on completion of tender offer and merger.								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Assertio is a U.S. based specialty oncology pharmaceutical company with established commercial capability of marketing and distribution of differentiated products.</p> <p>Assertio's portfolio includes ROLVEDON® (eflapegrastim xnst), approved as BLA by USFDA for long acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.</p> <p>ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive care market.</p> <p>Assertio is headquartered in Lake Forest, Illinois.</p> <p>Adjusted turnover of Assertio for ROLVEDON® (surviving product, post asset sale of products on April 8, 2026, to Cosette Pharmaceuticals Inc.) for past three years is as under:</p> <table border="1"> <thead> <tr> <th>CY</th> <th>Turnover (USD million)</th> </tr> </thead> <tbody> <tr> <td>2025</td> <td>68.23</td> </tr> <tr> <td>2024</td> <td>60.09</td> </tr> <tr> <td>2023 (Note 1)</td> <td>18.18</td> </tr> </tbody> </table> <p>Note 1: ROLVEDON® was acquired by Assertio on July 31, 2023 the turnover for CY 2023 is for a period of 5 months.</p>	CY	Turnover (USD million)	2025	68.23	2024	60.09	2023 (Note 1)	18.18
CY	Turnover (USD million)									
2025	68.23									
2024	60.09									
2023 (Note 1)	18.18									



**Zydus and Assertio Holdings enter into an agreement for Zydus to acquire Assertio  
in all-cash tender offer**

*Assertio is focused on specialty and oncology supportive-care therapies*

*Ahmedabad, India, 13 May 2026*

Zydus Lifesciences Limited (“Company”), an innovation-led global lifesciences company, today announced that Zydus Worldwide DMCC (“Zydus Worldwide”), a subsidiary of the Company has signed a definitive agreement, through its wholly owned acquisition subsidiary Zara Merger Sub Inc., (“Zara”) (Zydus Worldwide, Zara and the Company are collectively referred to as “Zydus”) with Assertio Holdings, Inc. a U.S.-based pharmaceutical company focused on specialty and oncology supportive-care therapies (NASDAQ: ASRT) (“Assertio”), to acquire all outstanding shares of Assertio for USD 23.50 per share in cash, representing total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method.

The acquisition provides Zydus with an established U.S. specialty oncology commercial platform, anchored by Assertio’s presence in oncology supportive care. Assertio’s portfolio includes ROLVEDON® (eflapegrastim-xnst), approved as a BLA by USFDA for long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive-care market. Zydus intends to leverage Assertio’s focused commercial infrastructure and oncology relationships to build and expand its specialty oncology presence in the U.S.

Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock. Following the successful completion of the tender offer, Zydus will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price paid in the tender offer.

The tender offer is expected to commence within five business days following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions.

Speaking on the development, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited, said, “This transaction represents a strategic step in strengthening our specialty and oncology footprint in the U.S. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally.”



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878

Paul Weiss, Rifkind, Wharton & Garrison LLP is serving legal counsel to Zydus. Moelis & Company LLC is serving as financial advisor to Assertio and Gibson, Dunn & Crutcher LLP is serving as its legal counsel.

#### **About Zydus Lifesciences Limited**

Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market to address unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details, visit [www.zyduslife.com](http://www.zyduslife.com).

#### **About Assertio Holdings, Inc.**

Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit [www.assertiotx.com](http://www.assertiotx.com).

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 regarding Zydus' proposed acquisition of Assertio, including statements regarding the prospective benefits of the proposed transaction, the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, and Assertio's products and commercial platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made and should not be relied upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will be achieved or will occur.

Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "might," "opportunity," "plan," "potential," "project," "seek," "should," "strategy," "target," "will," or the negative of these words and phrases, other variations of these words and phrases or comparable terminology.

Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to: (i) risks associated with the timing of the closing of the proposed transaction, including the risk that the proposed transaction may not be completed in a timely manner or at all; (ii) uncertainties as to how many of Assertio's stockholders will tender their shares in the



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

#### **Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878

tender offer; (iii) the possibility that competing offers or acquisition proposals for Assertio will be made; (iv) the possibility that any or all of the various conditions to the consummation of the tender offer may not be satisfied or waived, including the failure to receive any required regulatory approvals; (v) the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; (vi) the possibility of business disruptions due to transaction-related uncertainty or the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; (vii) the effect of the announcement or pendency of the proposed transaction on the Company's business and operating results, including the response of business partners and competitors and potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; (viii) risks related to the diverting of management's attention from the Company's ongoing business operations; (ix) general economic and market conditions; and (x) other factors as set forth from time to time in Assertio's filings with the SEC, including its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as well as the tender offer statement, solicitation/recommendation statement and other tender offer documents that will be filed by Zydus and Assertio, as applicable.

The foregoing list of factors is not exhaustive. You should not place undue reliance on any forward-looking statements. Actual results could differ materially due to various factors, risks and uncertainties. Neither Zydus nor Assertio assumes any obligation to update these forward-looking statements or to conform them to future events or developments, except as required by law. This press release does not constitute an offer to buy or a solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of Assertio's common stock will only be made pursuant to the tender offer materials described above under "Additional Information and Where to Find It."

#### **Additional Information and Where to Find It**

This press release does not constitute an offer to buy or a solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of Assertio's common stock will only be made pursuant to the tender offer materials described above under "Additional Information and Where to Find It."

The tender offer for the outstanding shares of Assertio common stock described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of Assertio, nor is it a substitute for the tender offer materials that Zydus and its wholly owned acquisition subsidiary, Zara Merger Sub, Inc. ("Merger Sub"), will file with the Securities and Exchange Commission (the "SEC") upon commencement of the tender offer. A solicitation and offer to buy shares of Assertio's common stock will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Zydus and Merger Sub intend to file with the SEC. In addition, Assertio will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

#### **Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878



Dedicated To Life

OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. INVESTORS AND STOCKHOLDERS OF ASSERTIO ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF ASSERTIO SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER.

The tender offer materials and the Solicitation/Recommendation Statement will be made available to all stockholders of Assertio at no expense to them. Once filed, investors will be able to obtain these documents, free of charge, at the website of the SEC at [www.sec.gov](http://www.sec.gov) or from the information agent named in the tender offer materials. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by Assertio under the "Investors" section of Assertio's website at [www.assertiotx.com](http://www.assertiotx.com). In addition to the tender offer materials and the Solicitation/Recommendation Statement, Zydus and Assertio file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Assertio with the SEC for free on the SEC's website at [www.sec.gov](http://www.sec.gov).

#### Contacts

##### Media

Sujatha Rajesh

Email: [sujatha.rajesh@zyduslife.com](mailto:sujatha.rajesh@zyduslife.com)

Mobile: 9974051180

##### Investors

Arvind Bothra

Email: [arvind.bothra@zyduslife.com](mailto:arvind.bothra@zyduslife.com)

Mobile: 9833853107



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

##### **Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878